Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 98,745 | 167,630 | 299,500 | 364,618 | 166,119 |
| Marketable Securities | 179,145 | 95,111 | 44,548 | N/A | N/A |
| Receivables | 60,588 | 55,928 | 48,864 | 29,760 | 16,990 |
| Inventories | 43,893 | 60,877 | 48,154 | 32,171 | 23,018 |
| TOTAL | $396,446 | $392,060 | $454,020 | $431,733 | $208,622 |
| Non-Current Assets | |||||
| PPE Net | 17,962 | 18,405 | 13,682 | 5,851 | 2,140 |
| Intangibles | 36,791 | 39,267 | 14,475 | 14,883 | 750 |
| Other Non-Current Assets | 48,301 | 44,725 | 37,299 | 10,838 | 8,467 |
| TOTAL | $103,054 | $102,397 | $65,456 | $31,572 | $11,357 |
| Total Assets | $499,500 | $494,457 | $519,476 | $463,305 | $219,979 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 5,529 | 3,032 | 4,805 | 3,034 | 2,944 |
| Accrued Expenses | 21,443 | 20,035 | 21,126 | 15,251 | 9,048 |
| Other current liabilities | 15,199 | 10,464 | 10,123 | 7,815 | 10,879 |
| TOTAL | $67,663 | $56,226 | $49,040 | $33,181 | $26,536 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,050 | 1,648 | 2,271 | N/A | N/A |
| Deferred Revenues | 25,492 | 22,695 | 12,986 | 7,081 | 3,665 |
| Other Non-Current Liabilities | 18,952 | 28,387 | 29,587 | 14,923 | 11,696 |
| TOTAL | $36,100 | $45,167 | $44,890 | $24,739 | $15,152 |
| Total Liabilities | $103,763 | $101,393 | $93,930 | $57,920 | $41,688 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 128,097 | 130,824 | 135,431 | 134,077 | N/A |
| Common Shares | 129 | 131 | 135 | 126 | 23 |
| Retained earnings | -35,199 | -29,178 | -17,030 | -19,606 | -22,607 |
| Other shareholders' equity | 16 | -1,275 | -446 | 1,240 | 194,384 |
| TOTAL | $395,737 | $393,064 | $425,546 | $405,385 | $178,291 |
| Total Liabilities And Equity | $499,500 | $494,457 | $519,476 | $463,305 | $219,979 |